Slide 1: Actualizing the Untapped Potential of the Innate Immune System
ACTUALIZING THE UNTAPPED POTENTIAL OF THE INNATE IMMUNE SYSTEM Affimed’s Approach to Advancing Immuno-Oncology Q3 2022 Financial Results & Operational Progress
Slide 2: Forward-Looking Statements / Cautionary Note
Forward-Looking Statements / Cautionary Note This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral
Slide 3: Adi Hoess, Chief Executive Officer
Adi Hoess Chief Executive Officer 3
Slide 4: Artiva Partnership: Extensive Diligence Confirmed Artiva is the Ideal Partner
Artiva Partnership: Extensive Diligence Confirmed Artiva is the Ideal Partner to Move the Combination of AFM13+cbNK Cells Forward Science: Partner must have an allogenic NK cell in clinical development with the data and platform to support clinical trials with Key Criteria Check List data validated
Slide 5: Pre-clinical Data Show Highly Synergistic Anti-tumor Activity of AFM13 With AB-101
Pre-clinical Data Show Highly Synergistic Anti-tumor Activity of the Combination of AFM13 With AB-101 NK Cells AFM13-mediated ADCC Lysis of Karpas-299 cells Imaging ofVolume Tumor tumor growth (BLI) 80 E:T ratio of 5:1 4×10 5 AB-101 Vehicle Vehicle AB-101 + AFM13 Mean counts/sec ±SD specific lysis [
Slide 6: Strategic Partnership with Artiva Enables Fastest Path Forward for AFM13
We Believe Strategic Partnership with Artiva Enables Fastest Path Forward for AFM13 in Combination with NK Cells Jointly develop, manufacture and commercialize a combination Purpose of therapy comprised of Affimed’s Innate Cell Engager (ICE®) AFM13 and Partnership Artiva’s cord blood-derived, cryopr
Slide 7: Andreas Harstrick, Chief Medical Officer
Andreas Harstrick Chief Medical Officer 7
Slide 8: A Growing Pipeline Poised to Advance the Treatment of Cancer
A Growing Pipeline Poised to Advance the Treatment of Cancer Broad Pipeline of Wholly Owned and Partnered Programs Candidate Approach Indication Discovery Ph. 1 Ph. 2a Ph. 2b Status Monotherapy Peripheral T-cell lymphoma (AFM13-202) Registration Directed, Completed Enrollment AFM13 + Adoptive NK cel
Slide 9: AFM13: AFM13-202 Completed Enrollment; AFM13-104 100% ORR at RP2D
AFM13: AFM13-202 Completed Enrollment; AFM13-104 100% ORR at RP2D Monotherapy Update: AFM13-202: Registration directed PTCL study under • Enrollment completed in January 2022; topline data expected in December 2022 protocol agreed with FDA ASH Abstract: NK Cell • As of July 31, 2022, 24 patients enr
Slide 10: AFM13+cbNK Cells Maintains a 100% ORR with 70.8% CR Rate
AFM13+cbNK Cells Maintains a 100% ORR with 70.8% CR Rate at the 1x108 per kg Dose Level – ASH Abstract 2022 Patient Case Study #2: CR of Multiple Disease Sites1 AT ENROLLMENT COMPLETE RESPONSE AFTER CYCLE 1 RR HL/ T-NHL Patients2 Unprecedented Results2 30 (28 HL/ 2 T-NHL) (24 patients at 1x108 per k
Slide 11: AFM24: Initiated Broad Development in Nine Cohorts
AFM24: Initiated Broad Development in Nine Cohorts with Additional Readouts Expected in Q2 and Q3 2023 Objectives: Establish a dosing regimen and assess safety and efficacy Monotherapy Update: Selected RP2D of 480 mg weekly flat dose; data from dose AFM24-101: Affimed-sponsored dose escalation prese
Slide 12: AFM24 SITC Update: Clinical Activity Observed with Atezolizumab Combination
AFM24 SITC Update: Clinical Activity Was Observed in Two Patients for the Combination of AFM24 with atezolizumab Update Case study Monotherapy An ongoing partial response was observed in a gastric cancer • Changes of NK cells in peripheral blood suggest patient who had previously progressed on 4 lin
Slide 13: AFM28: Designed to Improve Efficacy and Safety in AML
AFM28: Designed to Improve Efficacy and Safety in AML; to Prevent or Delay Relapse, and Work in R/R Disease AFM28 poster presentations at ASH 2021 & NK20221,2 • Greater cell surface retention on NK cells than conventional monoclonal antibodies • Activated NK cells more potently than an Fc-enhanced a
Slide 14: Angus Smith, Chief Financial Officer
Angus Smith Chief Financial Officer 14
Slide 15: Selected Balance Sheet and Cash Flow Metrics
Selected Balance Sheet and Cash Flow Metrics Balance Sheet As of As of September 30, 2022 December 31, 2021 (millions of €) (millions of €) Total Cash & Cash Equivalents 222.9 197.6 Cash Flow For the quarter ended For the quarter ended September 30, 2022 September 30, 2021 (millions of €) (millions
Slide 16: Selected Income Statement Metrics
Selected Income Statement Metrics For the quarter ended For the quarter ended September 30, 2022 September 30, 2021 (millions of €) (millions of €) Revenue 14.9 8.7 Other Income – net 0.1 0.2 Research & Development Expense (26.1) (20.6) General & Administrative Expense (8.1) (6.8) Operating income /
Slide 17: Adi Hoess, Chief Executive Officer
Adi Hoess Chief Executive Officer 17
Slide 18: Additional Near-Term Development Opportunities for AFM13
Additional Near-Term Development Opportunities for AFM13 to Provide Meaningful Benefit to Patients in Need AFM13 has potential to benefit patients across many indications Market Potential Monotherapy: 30,00 0 First Wave Second Wave Third Wave • Addresses PTCL NK cell combo: 25,00 0 • Addresses HL, P
Slide 19: Multiple Potential Inflection Points in 2022 – 2023
Multiple Potential Inflection Points in 2022 – 2023 Strong Cash Position Enables Focused Execution AFM13 • Monotherapy in PTCL: Enrollment completed in January 2022; topline data expected in mid-December 2022 • NK cell combination in CD30+ Lymphoma: data updates from AFM13-104 at ASH 2022; NK cell c
Slide 20: Driving the Revolution in Cancer Treatment
Driving the revolution in cancer treatment Inspired by the immense potential of the innate immune system (NK cells and macrophages), we are dedicated to unlocking profound possibilities through the development of our Innate Cell Engagers (ICE®) and to bringing new hope to those whose lives have been
Slide 21: Thank you!
Thank you! 21